Open access
Oct 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
The use of deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for the treatment of attacks of bradykinin-mediated angioedema, including hereditary angioedema, is supported and may address an unmet need for options that are effective and well tolerated, with convenient administr...
M. Riedl, P. Li, A. Adatia et al.
· The Lancet · 1 citation